Skip directly to search Skip directly to A to Z list Skip directly to site content
CDC Home

Volume 8, Number 5—May 2002

Perspective

Evaluation in Nonhuman Primates of Vaccines against Ebola Virus

Thomas W. Geisbert*, Peter Pushko*, Kevin Anderson*, Jonathan Smith*, Kelly J. Davis*, and Peter B. Jahrling*
Author affiliations: *U.S. Army Medical Research Institute of Infectious Diseases, Fort Detrick, Maryland, USA

Main Article

Table 1

Prechallenge neutralization titers of Ebola virus (EBOV)-vaccinated monkeys

Nonhuman primate species No. of animals Vector Antigen Neutralization titersa
Cynomolgus 3 Replicon GP 0, 0, 0
Cynomolgus 3 Replicon NP 0, 0, 0
Cynomolgus 3 Replicon GP + NP 0, 0, 10
Cynomolgus 3 Replicon Influenza HA 0, 0, 0
Cynomolgus 3 Vaccinia GP 10, 20, 20
Cynomolgus 3 Liposome Inactivated virion 20, 40, 80
Cynomolgus 2 Inactivated virion 10, 20
Rhesus 2 Inactivated virion 10b, 20
Cynomolgus 2 None 0, 0
Rhesus 2 None 0, 0

aImmunoglobulin G enzyme-linked immunosorbent assay, neutralizing antibody (PRNT50) All vaccinated monkeys seroconverted by enzyme-linked immunosorbent assay before challenge.
bAnimal survived challenge.
GP, glycoprotein; NP, nucleoprotein.

Main Article

Top of Page

USA.gov: The U.S. Government's Official Web PortalDepartment of Health and Human Services
Centers for Disease Control and Prevention   1600 Clifton Rd. Atlanta, GA 30333, USA
800-CDC-INFO (800-232-4636) TTY: (888) 232-6348 - Contact CDC–INFO